Commentary: A black eye for BASF and a heavy burden for Evonik
The rejection of the merger of the two largest German chemical companies is consistent, but bad news for the future of German and European chemicals.
The planned merger between BASF and Evonik AG has fallen through due to strong opposition, particularly in Nordrhein-Westfalen. As a result, Evonik's stock price dropped to 18 Euro, down from a potential 25 Euro per share that BASF was expected to pay. Evonik must now prove it can achieve a similar valuation as a standalone company.
The RAG-Stiftung, Evonik's main shareholder, relies on the company's dividends to cover mining legacy costs. BASF has ended its bid, avoiding a protracted and potentially costly takeover battle.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Chemie: BASF: Beenden Bemühungen um Übernahme von Evonik handelsblatt.com